Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 75/100

INOVIO to Present at Upcoming Scientific Conferences

Wednesday, April 9, 2025 2 min read
Key Takeaway: INOVIO (NASDAQ: INO) will present key data regarding its lead candidate, INO-3107, at various upcoming scientific conferences, including the National HPV Conference and the World Vaccine Congress. Notably, INO-3107 achieved a 72% overall response rate in treating recurrent respiratory papillomatosis associated with HPV. Additionally, the company will showcase discussions on their novel DNA-encoded monoclonal antibody technology at the World Vaccine Congress. The information and available abstracts will be disclosed on INOVIO's website following the presentations.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is presenting key data on INO-3107 at multiple significant conferences.
  • The company reports a 72% overall response rate for INO-3107 in its treatment of recurrent respiratory papillomatosis caused by HPV.
  • INOVIO's technology focuses on innovative DNA medicines that aim to combat various diseases.

Full Press Release Details

PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.
National HPV Conference (Indianapolis, IN)
Oral presentation: DNA Immunotherapy (INO-3107) Results in a 72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11
Panel: Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences – Moderated by Kim McClellan, RRP Foundation President
World Vaccine Congress (Washington, DC)
Oral presentation: A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb™) as Next Gen DNA Medicine
Oral presentation: DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases
Festival of Biologics (San Diego, CA)
Oral presentation: Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis
Available abstracts will be shared on INOVIO's website following presentations.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What is INOVIO's main focus?

INOVIO specializes in developing DNA medicines for HPV-related diseases, cancer, and infections.

What is INO-3107 used for?

INO-3107 targets recurrent respiratory papillomatosis caused by HPV-6 and HPV-11.

Where will INOVIO present its data?

INOVIO will present at the National HPV Conference and World Vaccine Congress.

What technology will INOVIO discuss at the conferences?

INOVIO will showcase its DNA-encoded monoclonal antibody technology at the events.

When will INOVIO share available abstracts?

INOVIO will post available abstracts on its website after the presentations.

Tags: INO Viatris Investor Conferences Healthcare INOVIO HPV DNA medicines recurrent respiratory papillomatosis
Last updated: Apr 9, 2025